Prevalence of diagnosed diabetes was 11.3 percent and undiagnosed diabetes was 4.5 percent; prevalence higher for men
WEDNESDAY, Nov. 6, 2024 (HealthDay News) — The prevalence of diabetes was 15.8 percent among U.S. adults during August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics.
Jane A. Gwira, M.D., M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from the National Health and Nutrition Examination Survey to examine the prevalence of diagnosed, undiagnosed, and total diabetes (excluding gestational diabetes) among U.S. adults during August 2021 to August 2023.
The researchers found that the prevalence of total diabetes was 15.8 percent, and the prevalence rates of diagnosed and undiagnosed diabetes were 11.3 and 4.5 percent, respectively, among U.S. adults during August 2021 to August 2023. Men had a higher prevalence of total and diagnosed diabetes than women (18.0 and 12.9 percent versus 13.7 and 9.7 percent). With age and with increasing weight status, there was an increase in the prevalence of total, diagnosed, and undiagnosed diabetes. Between 1999-2002 and August 2021 to August 2023, there was an increase in the age-adjusted prevalence of total and diagnosed diabetes.
“Slightly more than one-quarter of adults with diabetes had undiagnosed diabetes,” the authors write. “Continued monitoring of both diagnosed and undiagnosed diabetes will provide essential information about the prevalence of diabetes in adults in the United States.”
Very Low-Carb Diet Shows Greater Cardiometabolic Benefits Than Other Diets
Time-Restricted Eating May Help Patients With Type 1 Diabetes
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death
Food-Based Support Aids Type 2 Diabetes Outcomes
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA
Burden of Myocardial Dysfunction Elevated for Individuals With Psoriasis
2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists